Share Medtronic earnings ahead on November 24: Hugo expansion meets a reshaped business

EARNINGS & CATALYSTS · November 17, 2026

Medtronic earnings ahead on November 24: Hugo expansion meets a reshaped business

Medtronic reports before open on November 24. Expanded Hugo surgery clearance and the completed MiniMed separation put growth, spending and the new business mix in focus.

By Stocks To Buy Now AI Research · Published

551
Medtronic office building in Mounds View, Minnesota.
Archive photograph of Medtronic offices in Mounds View, Minnesota, May 2017. Photo: Tony Webster from Minneapolis, Minnesota, United States / Wikimedia Commons · CC BY 2.0 · Resized to at most 1200px wide and JPEG compressed; a smaller feed preview is available.
Financials
Technicals
Earnings & peers
Earnings calendar snapshot · dates in New York time
CompanyReport dateWindowEPS estimateRevenue estimate
Medtronic Plc (MDT)November 24, 2026Issuer confirmedBefore open1.339.48B

1) When are earnings and what should investors compare?

Medtronic confirms fiscal second-quarter 2027 results on November 24, 2026, before open, covering the period ended October 30. The company also confirms a webcast that morning. Results remain upcoming. The most useful benchmark will be the outlook for the business after the completed MiniMed separation. September’s companywide adjusted earnings outlook of $5.94–6.00 per share was issued before that separation; it should not be treated as a restated forecast for the remaining business. Adjusted earnings exclude certain costs, while reported earnings follow standard accounting rules.

2) Why does the Hugo clearance matter?

On November 17, Medtronic announced FDA clearance for general surgery procedures using its Hugo robotic-assisted surgery system, expanding beyond its earlier U.S. urology indication. The covered procedures represent about 3.5 million U.S. surgeries annually, according to the company. That expands the potential market, but it is not a sales forecast: hospitals must adopt the system, train teams and use it regularly. The clearance arrived after the October 30 quarter-end, making it an outlook catalyst rather than an explanation for revenue already earned in the coming report.

3) How do the last two reports compare with expectations?

Fiscal fourth-quarter 2026 sales were $9.807 billion and adjusted earnings per share, or EPS, were $1.55. Compared with Zacks estimates dated May 27, revenue was 1.5% above $9.66 billion and EPS was 0.6% below $1.56. Fiscal first-quarter 2027 sales of $9.756 billion and adjusted EPS of $1.45 were 3.0% and 4.3% above the August 25 estimates of $9.47 billion and $1.39. These deliberately dated, week-earlier estimates can differ from the final consensus on release day. Reported EPS was $0.96 and $1.14 respectively. Both quarters included the diabetes business. The first quarter also contained an extra fiscal week, which management estimated added about $570 million of revenue to its organic-growth calculation.

4) What does the price chart show?

Medtronic closed at $102.32 on November 17, 2026, above its 20-day average of $99.35 and 50-day average of $94.10. Recent lows suggest an approximate $100–101 support area, while early-November highs sit around $105–106. These are reference areas, not guaranteed turning points. Shares rose 5.7% from the June 2 close to the June 3 close after the fourth-quarter release, and 1.5% from the August 31 close to the September 1 close after the first-quarter release. Those full-day changes also reflect other market influences.

5) How should the financial images be read?

The five-year revenue history and fiscal 2026 business mix describe Medtronic before the MiniMed separation. They are not a forecast of the remaining company’s revenue. The illustrative equity value uses the November 17 closing price and August 28 outstanding shares, less the shares accepted in October’s exchange offer; it excludes other subsequent share changes. Valuation multiples are omitted because mixing a changed share count and business portfolio with older earnings could give a misleading comparison.

6) How the business makes money

Medtronic sells medical equipment, implants and related supplies used in heart care, spine and brain treatment, and surgery. Product adoption depends on clinical evidence, physician training, hospital budgets and reimbursement. Equipment placements can create further demand for instruments and supplies, so procedure usage matters alongside initial system sales.

7) What to watch

The central earnings question is how the remaining company converts its product pipeline into profitable growth. New Hugo indications expand the procedures it can serve, while heart-rhythm and ablation products offer another growth opportunity. Watch management’s explanation of underlying demand after last quarter’s extra fiscal week, launch spending, cash generation and the earnings effect of the completed MiniMed exchange. A clearer outlook could help investors assess the new business mix.

8) Recently reported peers

Boston Scientific provides relevant context through competing cardiovascular, neuromodulation and surgical-device businesses. On October 28 it reported third-quarter sales of $5.138 billion and adjusted EPS of $0.73, below Zacks estimates dated October 21 of $5.17 billion and $0.76 by 0.6% and 3.9%. Reported EPS was $0.40. It described a cyber incident that disrupted operations and issued fourth-quarter guidance for a 1–3% sales decline and adjusted EPS of $0.77–0.79. Shares fell 5.8% from the October 27 close to the October 28 close. Its company-specific disruption is a reminder to examine execution and product competition; it does not establish what Medtronic will report.

9) Risks into the report

Hospital purchasing delays, reimbursement changes, product safety issues and intense competition can slow adoption. Launch costs, acquisitions and tariffs can reduce the profit earned on higher sales. Separating MiniMed also changes revenue, earnings and shares outstanding, making headline year-over-year comparisons less useful until the continuing-business figures are reconciled. FDA clearance expands permitted use but does not guarantee commercial success.

10) Insider activity over the past three months

$0 bought and $5.89M sold in reported trades. 0% buy / 100% sell by value. 0 insiders bought only, 3 sold only, and 0 did both.

AI-assisted research. Earnings dates and estimates may change. Estimates are not reported results. Educational information; investing involves risk.

Explore the stocks in this report

EXPLORE COMPANY RESEARCH

Medtronic plc.: the full stock picture

Earnings history, financials, price action and peer comparisons — all below.
Open MDT stock page ↗

EXPLORE THE COMPANY

Medtronic plc. (MDT)

Explore earnings, price action, financials and industry comparisons.

Symbol
MDT
Sector
Healthcare
Industry
Medical Devices
Instrument type
EQUITY

Profile information from our saved company catalog. This is not a live quote or confirmation of current listing status.

EARNINGS & COMPANY RESEARCH

MDT earnings, valuation & price action

View in calendar ↗
NEXT EXPECTED REPORTNov 24 2026Before open · ET
EPS ESTIMATE1.33
REVENUE ESTIMATE9.48B

Expected dates may change. Estimates use the source’s reporting currency. Quotes and research are snapshots, not live prices.

COMPANY RESEARCH · Healthcare

Medtronic Plc MDT

Medical - Devices · Updated 11/17/2026

Adjusted closing price · USD102.32 Nov 17
718395107Nov 14May 19Nov 17
Price50-day average200-day average+10.3% in view
VALUATION & EXPECTATIONS
Trailing P/E25.7×
Forward P/E17.1×
Trailing P/S3.6×
Forward P/S3.4×
EPS beat rate100%
Revenue beat rate88%
Positive window50%

EPS beats: 8 of 8 comparable reports. Positive price windows: 4 of 8.

Market caps may be up to 14 days old; prices up to seven days old; ratios and analyst estimates up to fourteen days old. Forward multiples use consensus for the fiscal year ending 2027-04-24, not the next 12 months. Negative or unavailable earnings multiples show “N/A”. Forward ADR multiples are omitted when the currency/share basis is not reconciled.

50-day average93.92
200-day average87.17
RSI (14)62
20-day range93.03 – 104.96
Relative volume0.6×
1-year change+10.3%
Last eight reported earnings for MDT
Report dateEPS estimateEPS actualSurpriseResultRevenue actualPrice window*5 sessions*
Sep 1 20261.391.45+4.3%Beat9.76B+1.7%+1.4%
Jun 3 20261.541.55+0.6%Beat9.81B+11.1%+8.8%
Feb 17 20261.341.36+1.5%Beat9.02B-1.0%-2.8%
Nov 18 20251.311.36+3.8%Beat8.96B+4.2%+9.4%
Aug 19 20251.231.26+2.4%Beat8.58B+0.4%-0.7%
May 21 20251.581.62+2.5%Beat8.93B-6.3%-4.6%
Feb 18 20251.361.39+2.2%Beat8.29B-6.3%-2.5%
Nov 19 20241.251.26+0.8%Beat8.4B-4.0%-2.2%

*Adjusted close before the report date to the first (or fifth) trading close after it. This window can span two sessions and is not an isolated earnings-day return. Figures may be revised by the provider.

Smart Money activity

Recent insider and politician transactions, and disclosed fund positions for MDT.

Get Pro to see what insiders are doing ahead of earnings.

Explore insider trades, fund holdings and politician activity with an active Pro membership.

Checking membership…

MDT earnings previews and market catalysts

Medtronic earnings ahead on November 24: Hugo expansion meets a reshaped business
2026-11-17 · Medtronic reports before open on November 24. Expanded Hugo surgery clearance and the completed MiniMed separation put growth, spending and the new business mix in focus.

All upcoming earnings catalysts →

02 / FINANCIALS

Medtronic plc. financials

Revenue, earnings, cash flow and financial strength in one view.

Reporting currency unconfirmed.

Revenue
Net income
Gross profit
Operating income
EBITDA
Operating cash flow
Capital expenditure
Cash
Total assets
Total liabilities
Shareholder equity
Total debt
Net profit margin
Gross margin
Short interest: days to cover
How to read these financial metrics

Figures use the app’s saved statements for the displayed period, not a trailing-year total. Margins divide profit by revenue; quick ratio uses current assets less inventory divided by current liabilities. Compare dates and currencies before comparing companies.

03 / WHAT COMES NEXT

Medtronic plc. event catalysts

Company earnings and scheduled market events that may change expectations.

2026-11-24

MDT earnings

Watch reported results, management’s outlook and the share-price reaction.

See earnings expectations ↑
2026-11-188:30 AM ET

Housing starts & building permits

Housing is sensitive to interest rates. Watch permits for indications of future building activity.

Release schedule ↗Scheduled
2026-11-182:00 PM ET · expected

FOMC minutes

Methodology-based date; confirm the Fed calendar closer to release.

Release schedule ↗Rule-based date
2026-11-198:30 AM ET

Initial jobless claims

Use the multiweek trend to distinguish normal volatility from a sustained increase in layoffs.

Release schedule ↗Scheduled
2026-11-2010:00 AM ET

Consumer sentiment · final

Watch changes in inflation expectations as well as sentiment.

Release schedule ↗Scheduled
2026-11-20Contract-specific cutoff

Monthly options expiration

Check your contract. Position unwinds and hedging can affect trading volume.

Release schedule ↗Scheduled
2026-11-20Time not announced

Russell · membership list update

Track revisions before the effective date; index flows do not guarantee a price rise.

Release schedule ↗Scheduled
2026-11-258:30 AM ET

Durable goods orders

Read core capital-goods orders alongside the headline; aircraft orders can create large swings.

Release schedule ↗Scheduled
2026-11-258:30 AM ET

Initial jobless claims

Use the multiweek trend; a single reading can be noisy. Thanksgiving release moves to Wednesday.

Release schedule ↗Scheduled

Dates use U.S. Eastern time and can change. Calendar events provide context; they do not determine the direction of a stock move.

04 / SIDE BY SIDE

Compare MDT with its peers

Medical - Devices · Compare valuation, financial strength and price performance.

Companies with valuation data5
Peer median positive P/E27.6×
MDT P/E25.7×
MDT peer comparison: valuation
CompanyPriceMarket capP/EForward P/EP/SForward P/S
MDTMedtronic plc.2026-11-17 · USD102.32134.26B25.7×17.1×3.6×3.4×
688617.SSAPT Medical Inc.
AVRAnteris Technologies Global Corp.2026-11-18 · USD5.31571.11M244.9×103.1×
BSXBoston Scientific Corporation2026-11-16 · USD43.6966.4B19.3×13.8×3.2×3.2×
EWEdwards Lifesciences Corporation2026-11-17 · USD106.5657.43B56.3×35.5×8.6×8.5×
GNGBYGetinge AB (publ)
LIVNLivaNova PLC2026-11-17 · USD91.925.44B27.6×21.1×3.6×3.6×
MDT25.7×
BSX19.3×
EW56.3×
LIVN27.6×

The peer median excludes the selected stock and is based on 3 available positive multiples. P/E median excludes negative or missing earnings multiples. Peer reports can have different fiscal periods and currencies; values are not currency-converted.

05 / PEER ANALYSIS

Explore MDT alongside its peers

Medical Devices · 24 companies · Cached market data

Comparison

Compare companies

Tap a bubble to inspect a company, then × to hide it. Undo restores the last company hidden. Bubble area reflects market cap, with a minimum size for visibility.

Price / sales
0.0×03.2×50.08B6.4×100.16B9.6×150.24BSYK · Stryker Market cap: 129.3B Price / sales: 4.9×BSX · Boston Scientific Market cap: 66.4B Price / sales: 3.2×EW · Edwards Lifesciences Market cap: 57.43B Price / sales: 8.6×BIO · Bio-Rad Laboratories Market cap: 10.16B Price / sales: 3.9×BRKR · Bruker Market cap: 9.72B Price / sales: 2.8×LIVN · LivaNova Market cap: 5.44B Price / sales: 3.6×IART · Integra LifeSciencess C Market cap: 1.14B Price / sales: 0.7×MDT · Medtronic Plc Market cap: 134.26B Price / sales: 3.6×Hide MDT · Undo restores itMarket cap
MDTMedtronic Plc

Market cap: 134.26B
Price / sales: 3.6×

Valuation snapshot: 2026-11-17
8 of 24 companies have both plotted values.

P/S distribution

Trailing price-to-sales multiples · 8 companies

Median P/S3.6×
Middle 50%3.1× to 4.2×
MDT P/S3.6×
MDT
0.6×5.2×

Tap a bar to see the companies in that P/S range. MDT has a higher P/S than 38% of this group.

16 companies excluded from P/S statistics because sales are non-positive or the saved multiple is missing. Statistics include all valid positive values, including those outside the focused chart range.

Companies

Showing 8 of 24 matching companies · Largest market cap first

  • Market cap 185.36BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 134.26BP/E 25.7×P/S 3.6×Forward P/E Forward P/S Price snapshot: 2026-11-17
    ↗
  • Market cap 129.3BP/E 35.9×P/S 4.9×Forward P/E Forward P/S Price snapshot: 2026-11-18
    ↗
  • Market cap 66.4BP/E 19.3×P/S 3.2×Forward P/E Forward P/S Price snapshot: 2026-11-16
    ↗
  • Market cap 57.43BP/E 56.3×P/S 8.6×Forward P/E Forward P/S Price snapshot: 2026-11-17
    ↗
  • Market cap 32.95BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 25.64BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 22.67BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗

Explore industries

Open an industry for its comparison, valuation and companies.

U.S.-listed companies from the app’s catalog. Medians use saved positive P/E values; coverage and snapshot dates vary.

How this comparison works

Uses the saved companies from the same industry and listing market, including MDT, ordered by cached market cap. Company snapshots can have different dates; the web cache may cover fewer metrics and periods than the app.

Periods end at each company’s dated price snapshot. Change compares the latest saved observation with one at or before the selected period’s start. A daily price change uses consecutive saved sessions. Financial data updates quarterly, so short periods may show no change. Missing history and zero starting values are excluded; a negative starting value uses its absolute value as the denominator.

Metrics use saved ratios and percentages. Market caps use the listing market’s reporting currency; underlying financial statements may use different currencies. Circle sizes have a minimum for touch visibility, and an outlined circle indicates a missing market cap. These comparisons describe data, not recommendations or price predictions.

INDUSTRY COMPARISON

MDT industry peers

Medical Devices · Oct 16, 2026 · Closing-price performance

No industry peers are available in the current heatmap coverage.